Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Tony Daltorio

Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock

Pharmaceutical giant AstraZeneca PLC (AZN) is a specialist in cancer treatments. In fiscal year 2023, it derived $18.4 billion and 40% of its sales from oncology products.

So it’s not a surprise that the company decided to move into the latest, next-generation treatments for cancer - radiopharmaceutical drugs. On March 19, AstraZeneca announced it will buy Canadian drug developer Fusion Pharmaceuticals (FUSN) for $2.4 billion. The deal involves a $2 billion upfront cash transaction, with a total transaction value of $2.4 billion based on contingent, further payments.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.